should adaura trial results change practice in nsclc?
Published 3 years ago • 478 plays • Length 5:08Download video MP4
Download video MP3
Similar videos
-
10:50
jack west and julia rotow discuss adaura trial takeaways
-
24:30
s1 episode 4: managing lung cancer with neoadjuvant and adjuvant therapy
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
3:16
adaura phase iii trial data: practice changing?
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
5:12
adaura trial: tagrisso & resectable egfr - leading developments & current questions in lung cancer
-
11:12
for nsclc neoadjuvant adjuvant or both
-
2:06
adaura trial: osimertinib for early stage egfr nsclc - 2022 program: targeted therapies forum
-
6:23
adaura trial; early stage non–small cell lung cancer
-
11:41
the adaura trial: flaws and results - leading developments & current questions in lung cancer
-
1:05
xiuning le, md, phd, describes the adaura clinical study as an adjuvant treatment in nsclc
-
7:00
flaura trial: impact of os data in advanced nsclc
-
4:10
five year update on adaura clinical trial of tagrisso in egfr early stage nsclc.
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
5:54
key points from the adaura trial: osimertinib - targeted therapies in lung cancer 2023
-
8:06
adaura: osimertinib post-tumor resection in nsclc
-
4:24
reflections on the adaura study
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc